MicroRNA-936 Targets FGF2 to Inhibit Epithelial Ovarian Cancer Aggressiveness by Deactivating the PI3K/Akt Pathway

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Aug 3

PMID 31371979

Citations 12

Authors

Cuihong Li

Shunrui Yu

Shanshan Wu

Ying Ni

Zixuan Pan

Affiliations

Soon will be listed here.

Abstract

Purpose: MicroRNA-936 (miR-936) was previously reported to be dysregulated and involved in the development of non-small cell lung cancer and glioma. However, the functional roles of miR-936 in epithelial ovarian cancer (EOC) remain unclear. In this study, we aimed to evaluate miR-936 expression in EOC and investigate its regulatory role in EOC cell behavior.

Methods: The expression of miR-936 in EOC was measured by RT-qPCR. Cell proliferation, apoptosis, migration, and invasion in vitro, as well as tumor growth in vivo, were determined by CCK-8, flow cytometry, migration and invasion assays, and xenograft models in nude mice, respectively. Bioinformatics analysis, luciferase reporter assays, RT-qPCR, and Western blot analysis were performed to investigate the relationship between miR-936 and fibroblast growth factor 2 (FGF2).

Results: miR-936 expression was significantly downregulated in EOC tissues and cell lines. Low miR-936 expression was found to be correlated with the tumor size, FIGO stage, and lymphatic metastasis in EOC patients. Functional experiments indicated that ectopic miR-936 expression suppressed EOC cell proliferation, migration, and invasion; promoted cell apoptosis; and decreased tumor growth in vivo. In addition, the gene was verified to be a direct target of miR-936 in EOC cells. FGF2 expression levels were upregulated in EOC tissues and were inversely correlated with miR-936 expression. Furthermore, effects of FGF2 silencing were similar to those of miR-936 overexpression in EOC cells. Recovered FGF2 expression rescued the miR-936-induced inhibitory effects in EOC cells. Notably, miR-936 was able to deactivate the PI3K/Akt signaling pathway in EOC cells by regulating FGF2 both in vitro and in vivo.

Conclusion: Altogether, our findings provided initial evidence that miR-936 inhibits the aggressiveness of EOC cells in vitro and in vivo, at least partially, by targeting FGF2-mediated suppression of the PI3K/Akt pathway. Therefore, the miR-936/FGF2/PI3K/Akt pathway is a promising therapeutic target for the treatment of EOC patients.

Citing Articles

CircZCCHC2 (hsa_circ_0000854) promotes hepatocellular carcinoma progression through modulating miR-936/BTBD7 axis and activating Rho/ROCK2 pathway.

Yin J, Wang M, Chen J, Li H, Zhuo J, Lu B Noncoding RNA Res. 2024; 9(2):437-446.

PMID: 38511064 PMC: 10950570. DOI: 10.1016/j.ncrna.2023.12.004.

MicroRNAs, long non-coding RNAs, and circular RNAs and gynecological cancers: focus on metastasis.

Rezaee A, Ahmadpour S, Jafari A, Aghili S, Tamehri Zadeh S, Rajabi A Front Oncol. 2023; 13:1215194.

PMID: 37854681 PMC: 10580988. DOI: 10.3389/fonc.2023.1215194.

Small molecules with huge impacts: the role of miRNA-regulated PI3K pathway in human malignancies.

Kashani B, Zandi Z, Kaveh V, Pourbagheri-Sigaroodi A, Ghaffari S, Bashash D Mol Biol Rep. 2021; 48(12):8045-8059.

PMID: 34689281 DOI: 10.1007/s11033-021-06739-6.

In Silico Identification of miRNA-lncRNA Interactions in Male Reproductive Disorder Associated with COVID-19 Infection.

Sabetian S, Castiglioni I, Jahromi B, Mousavi P, Cava C Cells. 2021; 10(6).

PMID: 34204705 PMC: 8231607. DOI: 10.3390/cells10061480.

Circular RNA circ_0001162 promotes cell proliferation and invasion of glioma via the miR-936/ERBB4 axis.

Zhou D, Lin X, Wang P, Yang Y, Zheng J, Zhou D Bioengineered. 2021; 12(1):2106-2118.

PMID: 34057019 PMC: 8806513. DOI: 10.1080/21655979.2021.1932221.

References

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

De Cecco L, Marchionni L, Gariboldi M, Reid J, Lagonigro M, Caramuta S . Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene. 2004; 23(49):8171-83. DOI: 10.1038/sj.onc.1207979. View

Cannistra S . Cancer of the ovary. N Engl J Med. 2004; 351(24):2519-29. DOI: 10.1056/NEJMra041842. View

Grose R, Dickson C . Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. 2005; 16(2):179-86. DOI: 10.1016/j.cytogfr.2005.01.003. View

Whitworth M, Backen A, Clamp A, Wilson G, McVey R, Friedl A . Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. Clin Cancer Res. 2005; 11(12):4282-8. DOI: 10.1158/1078-0432.CCR-04-1386. View

Mendell J . MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle. 2005; 4(9):1179-84. DOI: 10.4161/cc.4.9.2032. View

Wu L, Belasco J . Let me count the ways: mechanisms of gene regulation by miRNAs and siRNAs. Mol Cell. 2008; 29(1):1-7. DOI: 10.1016/j.molcel.2007.12.010. View

Nam E, Yoon H, Kim S, Kim H, Kim Y, Kim J . MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008; 14(9):2690-5. DOI: 10.1158/1078-0432.CCR-07-1731. View

Deng Z, Cao H, Hu Y, Wen J, Zhou J . TRX is up-regulated by fibroblast growth factor-2 in lung carcinoma. APMIS. 2010; 119(1):57-65. DOI: 10.1111/j.1600-0463.2010.02692.x. View

10.

Zhang B, Cai F, Zhong X . An overview of biomarkers for the ovarian cancer diagnosis. Eur J Obstet Gynecol Reprod Biol. 2011; 158(2):119-23. DOI: 10.1016/j.ejogrb.2011.04.023. View

11.

Feng Q, Shi H, Qiao L, Zhao J . [Expression of hSef and FGF-2 in epithelial ovarian tumor]. Zhonghua Zhong Liu Za Zhi. 2012; 33(10):770-4. View

12.

Lau M, So W, Leung P . Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLoS One. 2013; 8(3):e59083. PMC: 3598697. DOI: 10.1371/journal.pone.0059083. View

13.

Sooman L, Freyhult E, Jaiswal A, Navani S, Edqvist P, Ponten F . FGF2 as a potential prognostic biomarker for proneural glioma patients. Acta Oncol. 2014; 54(3):385-94. DOI: 10.3109/0284186X.2014.951492. View

14.

Dinkelspiel H, Champer M, Hou J, Tergas A, Burke W, Huang Y . Long-term mortality among women with epithelial ovarian cancer. Gynecol Oncol. 2015; 138(2):421-8. PMC: 4522327. DOI: 10.1016/j.ygyno.2015.06.005. View

15.

Chang S, Bristow R, Chi D, Cliby W . Role of aggressive surgical cytoreduction in advanced ovarian cancer. J Gynecol Oncol. 2015; 26(4):336-42. PMC: 4620371. DOI: 10.3802/jgo.2015.26.4.336. View

16.

Litwin M, Radwanska A, Paprocka M, Kieda C, Dobosz T, Witkiewicz W . The role of FGF2 in migration and tubulogenesis of endothelial progenitor cells in relation to pro-angiogenic growth factor production. Mol Cell Biochem. 2015; 410(1-2):131-42. DOI: 10.1007/s11010-015-2545-5. View

17.

Li W, Du X, Chen Q, Kang Y, Xu C, Fan L . Peptidomimetic suppresses proliferation and invasion of gastric cancer cells by fibroblast growth factor 2 signaling cascade blockage. Anticancer Drugs. 2015; 27(3):164-72. DOI: 10.1097/CAD.0000000000000312. View

18.

He Q, Ren X, Chen J, Li Y, Tang X, Wen X . miR-16 targets fibroblast growth factor 2 to inhibit NPC cell proliferation and invasion via PI3K/AKT and MAPK signaling pathways. Oncotarget. 2015; 7(3):3047-58. PMC: 4823089. DOI: 10.18632/oncotarget.6504. View

19.

Pal M, Jaiswar S, Dwivedi V, Tripathi A, Dwivedi A, Sankhwar P . MicroRNA: a new and promising potential biomarker for diagnosis and prognosis of ovarian cancer. Cancer Biol Med. 2016; 12(4):328-41. PMC: 4706521. DOI: 10.7497/j.issn.2095-3941.2015.0024. View

20.

Shi H, Xu J, Zhao R, Wu H, Gu L, Chen Y . FGF2 regulates proliferation, migration, and invasion of ECA109 cells through PI3K/Akt signalling pathway in vitro. Cell Biol Int. 2016; 40(5):524-33. DOI: 10.1002/cbin.10588. View